Compositions and methods of use for osteoclast inhibitor factors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 16, 1999
Issued Date -
N/A
app pub date -
Aug 25, 1998
filing date -
Dec 20, 1996
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
It has been found that two proteins produced by human osteoclasts inhibit osteoclast formation in bone marrow cultures and inhibit bone resorption in a fetal long bone assay. One of the proteins is identical to an Ly6 gene family protein and homologous to the Sca2 antigen, Ly6A. The second, OIP-2, is a novel protein not previously identified. The discovery of the osteoclast inhibition property of the OIP proteins suggests the therapeutic potential for patients with disordered osteoclast activity in such conditions as osteoporosis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully